StreetInsider.com News Articles

Presitge Brands (PBH) PT Lowered to $72 at Canaccord

Fri, 15 May 2026 06:43:35 -0400

(Updated - May 15, 2026 6:43 AM EDT)

Canaccord analyst Susan Anderson lowered the price target on Presitge Brands (NYSE: PBH) to $72.00 (from $86.00) while maintaining a Buy rating.

The analyst commented: 'On 5/13 after the close, PBH reported 4Q26 (Mar-end) results with sales down -5.0% to $281.6M, missing implied guidance of ~$293M. The miss was driven primarily by continued eye care weakness coupled with incremental pressure from the Iran conflict. PBH also announced another acquisition, LaCorium Health, which is an Australian based portfolio of brands that focus on therapeutic skin care. The $150M all-cash deal is expected to close in

Presitge Brands (PBH) PT Lowered to $72 at Canaccord

Fri, 15 May 2026 06:43:35 -0400

(Updated - May 15, 2026 6:43 AM EDT)

Canaccord analyst Susan Anderson lowered the price target on Presitge Brands (NYSE: PBH) to $72.00 (from $86.00) while maintaining a Buy rating.

Form 10-K Prestige Consumer Health For: Mar 31

Thu, 14 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260514/26495832.html

Form 10-K Prestige Consumer Health For: Mar 31

Thu, 14 May 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260514/26495832.html

Form 4/A Prestige Consumer Health For: May 02 Filed by: Sacco Christine

Thu, 14 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26494375.html

Form 4/A Prestige Consumer Health For: May 02 Filed by: Sacco Christine

Thu, 14 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260514/26494375.html

Oppenheimer Downgrades Presitge Brands (PBH) to Perform

Thu, 14 May 2026 05:12:34 -0400

Oppenheimer analyst Rupesh Parikh downgraded Presitge Brands (NYSE: PBH) from Outperform to Perform.

For an analyst ratings summary and ratings history on Presitge Brands click here. For more ratings news on Presitge Brands click here.

Shares of Presitge Brands closed at $51.81 yesterday.

Prestige Brands (PBH) Misses Q4 EPS by 16c ; Offers Guidance

Thu, 14 May 2026 02:14:29 -0400

Prestige Brands (NYSE: PBH) reported Q4 EPS of $1.23, $0.16 worse than the analyst estimate of $1.39. Revenue for the quarter came in at $281.6 million versus the consensus estimate of $295.23 million.

GUIDANCE:

Prestige Brands sees FY2027 EPS of $4.42-$4.51, versus the consensus of $4.54. Prestige Brands sees FY2027 revenue of $1.1-1.12 billion, versus the consensus of $1.1 billion.

For earnings history and earnings-related data on Prestige Brands (PBH) click here.

Prestige Brands (PBH) Misses Q4 EPS by 16c ; Offers Guidance

Thu, 14 May 2026 02:14:29 -0400

GUIDANCE:

Prestige Brands sees FY2027 EPS of $4.42-$4.51, versus the consensus of $4.54. Prestige Brands sees FY2027 revenue of $1.1-1.12 billion, versus the consensus of $1.1 billion.

For earnings history and earnings-related data on Prestige Brands (PBH) click here.

Form 8-K Prestige Consumer Health For: May 13

Wed, 13 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260513/26486881.html

Form 8-K Prestige Consumer Health For: May 13

Wed, 13 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260513/26486881.html

Prestige Consumer Healthcare reports mixed fiscal 2026 results, announces LaCorium deal

Wed, 13 May 2026 16:30:26 -0400

Prestige Consumer Healthcare Inc. (NYSE: PBH) reported fiscal 2026 revenues of $1,088.7 million, down 4.3% from the prior year's $1,137.8 million, according to a statement based on company results released May 13.

The consumer healthcare company posted diluted earnings per share of $3.91 for fiscal 2026, compared to $4.29 in the previous year. On an adjusted basis, diluted earnings per share reached $4.38, down from $4.52 in fiscal 2025.

Fourth quarter revenues totaled $281.6 million, representing a 5.0% decrease from $296.5 million in the same period last year. The revenue decline was primarily attributed to lower Eye & Ear Care category sales,

Prestige Consumer Healthcare reports fiscal 2026 results, plans LaCorium buy

Wed, 13 May 2026 16:30:20 -0400

Prestige Consumer Healthcare Inc. (NYSE: PBH) reported revenues of $1.09 billion for fiscal year 2026, down 4.3% from $1.14 billion in the prior year. The company posted diluted earnings per share of $3.91, compared to $4.29 in fiscal 2025.

For the fourth quarter ended March 31, 2026, revenues totaled $281.6 million, a 5.0% decrease from $296.5 million in the same period last year. The revenue decline was primarily attributed to lower Eye & Ear Care category sales due to limited supply capacity for Clear Eyes products.

The company announced a definitive agreement to acquire LaCorium Health for approximately $150 million in cash.

Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health

Wed, 13 May 2026 16:30:00 -0400

Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026
Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026
Announces agreement to acquire LaCorium Health, a leader in Australian therapeutic skin care
Introducing Outlook for Fiscal 2027 Organic Revenue Growth and Adjusted Diluted EPS of 1% to 3%, respectively, excluding the impact of acquisitions

TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.

“Our fiscal 2026 demonstrated the resilience of

Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health

Wed, 13 May 2026 16:30:00 -0400

Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026
Diluted EPS of $3.91 and Adjusted Diluted EPS of $4.38 in fiscal year 2026
Announces agreement to acquire LaCorium Health, a leader in Australian therapeutic skin care
Introducing Outlook for Fiscal 2027 Organic Revenue Growth and Adjusted Diluted EPS of 1% to 3%, respectively, excluding the impact of acquisitions

TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.

“Our fiscal 2026 demonstrated the resilience of

Form 4 Prestige Consumer Health For: May 11 Filed by: Zerillo Jeffrey

Tue, 12 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260512/26477449.html

Form 4 Prestige Consumer Health For: May 11 Filed by: Zerillo Jeffrey

Tue, 12 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260512/26477449.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Sacco Christine

Mon, 11 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260511/26468758.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Sacco Christine

Mon, 11 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260511/26468758.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Zerillo Jeffrey

Mon, 11 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260511/26468777.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Zerillo Jeffrey

Mon, 11 May 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260511/26468777.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Lombardi Ronald M.

Mon, 11 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260511/26468735.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Lombardi Ronald M.

Mon, 11 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260511/26468735.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Mekhail Adel

Mon, 11 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260511/26468655.html

Form 4 Prestige Consumer Health For: May 07 Filed by: Mekhail Adel

Mon, 11 May 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260511/26468655.html